The race to gain an even larger share of the transcatheter aortic valve replacement (TAVR) market is officially underway. Dublin-based Medtronic plc. said it received FDA approval for a trial for an expanded indication for the Corevalve Evolut R system. The indication would target patients with aortic stenosis, who are at a low surgical mortality risk as determined by a heart team. Read More
